Point72 Asset Management
RPRX icon

Point72 Asset Management’s Royalty Pharma RPRX Stock Holding History

Point72 Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-123,100
Closed -$4.34M – 4130
2025
Q3 		$4.34M Sell
123,100
-6,000
-5% -$217K 0.01% 1119
2025
Q2 		$4.65M Hold
129,100
– – 0.01% 999
2025
Q1 		$4.02M Buy
+129,100
New +$4.09M 0.01% 1004

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Point72 Asset Management's RPRX Position: Q1 2026 in Review

Point72 Asset Management reduced its Royalty Pharma (RPRX) stake by 8.3% in Q1 2026, selling an estimated $1.94M and leaving 490,018 shares worth $23.5M. The position accounts for 0.03% of the portfolio, ranked #717.

Point72 Asset Management first reported a position in RPRX in Q3 2021 and has held it in 12 quarters since. The position peaked at $73.7M in Q1 2022. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Point72 Asset Management held 490,018 shares of Royalty Pharma worth $23.5M as of Q1 2026.
  • Point72 Asset Management sold 44,288 Royalty Pharma shares in Q1 2026, an estimated $1.94M.
  • Royalty Pharma made up 0.03% of Point72 Asset Management's portfolio in Q1 2026, its #717 holding.
  • Point72 Asset Management first reported a position in Royalty Pharma in Q3 2021 and has held it in 12 quarters since.
  • Point72 Asset Management's Royalty Pharma position peaked at $73.7M in Q1 2022.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.